S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
1970’s computer coder issues shocking A.I. warning (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
1970’s computer coder issues shocking A.I. warning (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
1970’s computer coder issues shocking A.I. warning (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
1970’s computer coder issues shocking A.I. warning (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free KZIA Stock Alerts
$0.38
+0.03 (+8.67%)
(As of 04/19/2024 ET)
Compare
Today's Range
$0.33
▼
$0.41
50-Day Range
$0.20
▼
$0.46
52-Week Range
$0.19
▼
$1.54
Volume
296,186 shs
Average Volume
765,916 shs
Market Capitalization
$6.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Kazia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.16mentions of Kazia Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.40) to ($0.33) Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.31 out of 5 stars

See Top Rated MarketRank™ Stocks Here
KZIA stock logo

About Kazia Therapeutics Stock (NASDAQ:KZIA)

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

KZIA Stock Price History

KZIA Stock News Headlines

April 16, 2024 | americanbankingnews.com
Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interest
March 20, 2024 | morningstar.com
Kazia Therapeutics Ltd ADR KZIA
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
March 16, 2024 | finance.yahoo.com
KZIA Apr 2024 2.500 call
March 13, 2024 | prnewswire.com
Kazia announces presentation of new data at AACR Annual Meeting
February 21, 2024 | msn.com
What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?
February 21, 2024 | finanznachrichten.de
Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
February 21, 2024 | finance.yahoo.com
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
February 21, 2024 | prnewswire.com
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
February 19, 2024 | thestreet.com
Kazia Therapeutics Limited
February 14, 2024 | wsj.com
Kazia Therapeutics Ltd. ADR
February 13, 2024 | nasdaq.com
Viking Therapeutics, Inc. Common Stock (VKTX)
January 18, 2024 | finance.yahoo.com
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
December 15, 2023 | msn.com
Kazia Therapeutics files to sell 591,697 ADSs for holders
December 5, 2023 | finance.yahoo.com
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
December 1, 2023 | marketwatch.com
Kazia Therapeutics Shares Tumble on $2 Million Direct Offering
December 1, 2023 | markets.businessinsider.com
Kazia Therapeutics Announces Registered Direct Offering - Quick Facts
December 1, 2023 | finance.yahoo.com
Kazia Therapeutics Announces $2 Million Registered Direct Offering
November 29, 2023 | msn.com
Kazia stock jumps after proposed license deal for paxalisib outside oncology
November 29, 2023 | markets.businessinsider.com
Kazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of Oncology
November 29, 2023 | marketwatch.com
Kazia Therapeutics Signs Letter of Intent for Paxalisib Development, Commercialization
November 29, 2023 | finance.yahoo.com
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
November 21, 2023 | finance.yahoo.com
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
November 20, 2023 | msn.com
Kazia Therapeutics gets deficiency notice from Nasdaq
November 18, 2023 | finance.yahoo.com
Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week
November 15, 2023 | finance.yahoo.com
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
See More Headlines
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KZIA
CUSIP
N/A
CIK
1075880
Web
www.kaziatherapeutics.com
Phone
(129) 472-4101
Fax
61-2-9476-0388
Employees
2,021
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.71
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
302.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
0.74

Miscellaneous

Outstanding Shares
16,340,000
Free Float
16,178,000
Market Cap
$6.05 million
Optionable
Optionable
Beta
2.12
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. John Edwin Friend II (Age 54)
    M.D., CEO, MD & Director
    Comp: $721.62k
  • Ms. Gabrielle Heaton BBUS (ACC)
    CPA, Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer
  • Ms. Anna Sandham
    Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed in 2024?

Kazia Therapeutics' stock was trading at $0.4395 at the start of the year. Since then, KZIA stock has decreased by 14.4% and is now trading at $0.3760.
View the best growth stocks for 2024 here.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 259,500 shares, an increase of 6.9% from the March 15th total of 242,800 shares. Based on an average trading volume of 838,400 shares, the days-to-cover ratio is currently 0.3 days.
View Kazia Therapeutics' Short Interest.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Telesis Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA).

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZIA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
1970’s computer coder issues shocking A.I. warning
TradeSmith
Top 5 AI Stocks to Buy for 2024
Market Moving Trends